AMERICAN SHARED HOSPITAL SERVICES AMS

Healthcare SIC 8071 - Services-Medical Laboratories NAICS Health Care and Social Assistance › Ambulatory Health Care Services › Medical and Diagnostic Laboratories › Medical Laboratories derived NYSE

American Shared Hospital Services ("ASHS" and, together with its subsidiaries, the "Company") is a leading provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. The main drivers of the Company's revenue are numbers of sites, procedure volume, and reimbursement. The Company delivers radiation therapy through medical equipment leasing and direct patient services, its two reportable segments. The medical equipment leasing segment, which we also refer to as the Company's leasing segment, operates by fee-per-use contracts or revenue sharing contracts where the Company shares in the revenue and operating costs of the equipment. The Company's facilities in Rhode Island, Peru, Ecuador, and Mexico are considered direct patient services, where a contract exists between the Company's facilities and the individual treated at the facility.

Last close 1.43 2026-09-04
Market cap $9.5M 2026-06-30 share count
52-week range 1.25 - 3.11

Valuation FY2025 figures against the last close

P/S0.3x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.23

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $28.1M$28.3M$21.3M$19.7M$17.6M$17.8M$20.6M$19.7M$19.6M$18.7M
Cost of revenue $23.0M$19.2M$12.0M$11.4M$10.9M$13.4M—$12.2M$10.9M$9.9M
Gross profit $5.1M$9.2M$9.3M$8.4M$6.7M$4.5M$6.9M$7.5M$8.7M$8.8M
SG&A $7.1M$7.4M$7.0M$5.1M$4.5M$4.6M$4.1M$4.0M$4.3M$3.8M
Total operating expenses —————$13.4M$13.7M$12.2M$10.9M—
Operating income -$3.6M-$2.8M$270.0K$2.4M$1.4M-$9.5M$1.5M$1.9M$2.4M$3.3M
Interest expense $1.6M$1.5M$1.1M$806.0K$739.0K$1.1M$1.3M$1.6M$1.9M$1.7M
Pre-tax income -$3.2M$1.2M$696.0K$2.5M$947.0K-$9.5M$1.6M$2.1M$1.8M$3.2M
Income tax $493.0K$295.0K$431.0K$963.0K$269.0K$1.7M$128.0K$451.0K$1.1M$943.0K
Net income -$1.6M$2.2M$610.0K$1.3M$194.0K-$7.1M$659.0K$1.0M$1.9M$930.0K
EPS, basic -0.230.340.100.210.03-1.140.110.180.330.17
EPS, diluted -0.230.330.100.210.03-1.140.110.170.330.17
Shares, diluted (wtd. avg.) 6.6M6.7M6.4M6.3M6.1M6.2M5.9M5.9M5.9M5.6M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $3.5M$11.0M$13.7M$12.3M$8.1M$4.0M$1.4M$1.8M$2.5M$3.1M
Receivables $10.5M$11.6M$4.3M$3.8M$4.2M$4.3M$6.9M$5.5M$5.0M$4.1M
Total current assets $17.7M$26.3M$20.5M$18.7M$15.1M$10.8M$10.7M$9.9M$8.9M$7.9M
Property, plant and equipment ——————$41.5M$46.7M$48.5M$51.3M
Goodwill $1.3M$1.3M$1.3M$1.3M$1.3M$1.3M$0———
Other intangibles $78.0K$78.0K$78.0K$78.0K$78.0K$78.0K$0———
Total assets $55.5M$60.2M$48.2M$44.0M$45.4M$43.7M$53.8M$57.5M$58.2M$60.6M
Accounts payable $607.0K$1.6M$315.0K$230.0K$318.0K$683.0K$557.0K$435.0K$359.0K$319.0K
Short-term debt $17.3M$2.8M$2.1M$1.3M$1.1M$1.2M$1.5M$2.1M$2.5M$2.2M
Total current liabilities $23.4M$10.4M$10.8M$5.2M$5.9M$12.4M$8.2M$9.5M$9.0M$8.7M
Long-term debt $0$17.3M$11.0M$12.2M$14.3M$3.4M$2.0M$3.3M$3.6M$5.1M
Total liabilities $27.8M$30.2M$21.9M$18.3M$21.2M—————
Retained earnings $4.3M$5.8M$3.6M$3.0M$1.7M$1.5M$8.6M$7.9M$6.9M$5.0M
Total equity $24.0M$25.2M$26.3M$25.6M$24.2M$23.6M$31.8M$31.0M$29.9M$27.2M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $3.1M$167.0K$5.7M$7.2M$6.3M$9.7M$8.0M$8.1M$7.9M$8.4M
Depreciation and amortisation ——$5.2M$4.8M$5.0M$7.0M$7.4M$6.8M$6.7M$6.3M
Stock-based compensation $404.0K$373.0K$389.0K$399.0K$420.0K$299.0K$230.0K$223.0K$323.0K$215.0K
Capital expenditure $7.6M$7.9M$6.3M$388.0K$1.7M$455.0K$990.0K$1.6M$803.0K$1.0M
Investing cash flow -$7.6M-$7.1M-$6.3M-$388.0K-$1.7M-$2.4M-$990.0K-$1.5M-$653.0K-$1.0M
Financing cash flow -$3.0M$4.4M$1.9M-$2.7M-$655.0K-$4.8M-$7.1M-$7.2M-$7.8M-$6.5M
Buybacks —————————$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-014145.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -10M 0 10M 20M 30M Revenue, FY2016: 18.7M Gross profit, FY2016: 8.8M Net income, FY2016: 930K Revenue, FY2017: 19.6M Gross profit, FY2017: 8.7M Net income, FY2017: 1.9M Revenue, FY2018: 19.7M Gross profit, FY2018: 7.5M Net income, FY2018: 1M Revenue, FY2019: 20.6M Gross profit, FY2019: 6.9M Net income, FY2019: 659K Revenue, FY2020: 17.8M Gross profit, FY2020: 4.5M Net income, FY2020: -7.1M Revenue, FY2021: 17.6M Gross profit, FY2021: 6.7M Net income, FY2021: 194K Revenue, FY2022: 19.7M Gross profit, FY2022: 8.4M Net income, FY2022: 1.3M Revenue, FY2023: 21.3M Gross profit, FY2023: 9.3M Net income, FY2023: 610K Revenue, FY2024: 28.3M Gross profit, FY2024: 9.2M Net income, FY2024: 2.2M Revenue, FY2025: 28.1M Gross profit, FY2025: 5.1M Net income, FY2025: -1.6M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $18.7M $19.6M $19.7M $20.6M $17.8M $17.6M $19.7M $21.3M $28.3M $28.1M
Gross profit $8.8M $8.7M $7.5M $6.9M $4.5M $6.7M $8.4M $9.3M $9.2M $5.1M
Net income $930.0K $1.9M $1.0M $659.0K -$7.1M $194.0K $1.3M $610.0K $2.2M -$1.6M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Debt acceleration or default Something has triggered a lender's right to demand early repayment - usually a covenant breach. Item 2.04
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 8071

TickerCompanyMarket capP/ERevenue growth
NTRA Natera, Inc. $47.31B — 35.9%
LH LABCORP HOLDINGS INC. $26.51B 31.3x 7.2%
DGX QUEST DIAGNOSTICS INC $26.17B 27.1x 11.8%
GH Guardant Health, Inc. $21.66B — 32.9%
CAI Caris Life Sciences, Inc. $7.08B — 97.0%
RDNT RadNet, Inc. $5.80B — 11.5%
CELC Celcuity Inc. $4.68B — —
BLLN BillionToOne, Inc. $4.61B 709.9x 100.0%